Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of EMPAGLIFLOZIN vs. JARDIANCE®
NCT07479108Completed
- Sponsor
- Adium Pharma
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Adium Pharma. Primary endpoints: Maximum Concentration at 72 hours and Area Under the Curve from time 0 to t at 72 hours. Started Nov 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07479108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479108.